Processa Pharmaceuticals

$6.95
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.20 (+2.96%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell PCSA and other stocks, options, and ETFs commission-free!

About PCSA

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its product pipeline is PCS499, which is use for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on October 2, 2017 and is headquartered in Hanover, MD. The listed name for PCSA is Processa Pharmaceuticals, Inc. Common Stock.

CEO
David Young
Employees
13
Headquarters
Hanover, Maryland
Founded
2017
Market Cap
73.43M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
19.50K
High Today
$6.95
Low Today
$6.47
Open Price
$6.75
Volume
32.10K
52 Week High
$11.00
52 Week Low
$3.40

Collections

PCSA Earnings

-$0.55
-$0.37
-$0.18
$0.00
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 12, After Hours

You May Also Like

PCY
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure